Infiltrating solid tumors with engineered T cells

Immuno-Oncology Insights 2021; 2(1), 1–8


Published: 4 February 2021
Alfonso Quintás-Cardama, MD

Alfonso Quintás-Cardama joined TCR² Therapeutics in 2017 as Chief Medical Officer. He brings nearly two decades of experience leading clinical strategy and regulatory filings for multiple oncology therapeutics resulting in market approval. Dr. Quintás-Cardama was the clinical development head of the Cell & Gene Therapies Unit at GlaxoSmithKline where he was responsible for the full clinical development strategy, execution and collaboration with Adaptimmune on affinity enhanced T-cell therapies. Previously, he served as Global Clinical Leader of Novartis’ now approved Kymriah™ (tisagenlecleucel) CTL019 program and was an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center. Dr. Quintás-Cardama earned his MD from the Universidad de Santiago de Compostela School of Medicine in Spain. He completed an internship and residency in the Department of Medicine, Albert Einstein College of Medicine in New York and a Hematology and Oncology fellowship at The University of Texas, MD Anderson Cancer Center.